LitAlert ~~ GeneLit.com

    • Effect of Risk-Reducing Salpingo-Oophorectomy on Sex-Steroid Hormone Serum Levels among Post-Menopausal Women: An NRG Oncology/GOG Study.
    • Mai PL, Miller A, Black A, Falk RT, Boggess JF, Tucker K, Stuckey AR, Rodriguez GC, Wong C, Amatruda TT, Wilkinson KJ, Modesitt SC, Yamada SD, Bixel KL, Glaser GE, Rose PG, Greene MH, Sherman ME.
    • Am J Obstet Gynecol. 2021 Feb 22. pii: S0002-9378(22)00124-7. doi: 10.1016/j.ajog.2022.02.022. Epub ahead of print.
    • Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study.
    • Miller RS, Mokiou S, Taylor A, Sun P, Baria K.
    • Breast Cancer Res Treat. 2022 Feb 22. doi: 10.1007/s10549-022-06541-3. Epub ahead of print.
    • Estimating the proportion of pathogenic variants from breast cancer case-control data: application to calibration of ACMG/AMP variant classification criteria.
    • James PA, Fortuno C, Li N, Lim BWX, Campbell IG, Spurdle AB.
    • Hum Mutat. 2022 Feb 22. doi: 10.1002/humu.24357. Epub ahead of print.
    • PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer.
    • Nelson R.
    • Medscape. 2022 Feb 22.
    • Genetic medicine is accelerating in Japan.
    • Hayashi S, Kubo M, Kaneshiro K, Kai M, Yamada M, Morisaki T, Takao Y, Shimazaki A, Shikada S, Nakamura M.
    • Breast Cancer. 2022 Feb 21. doi: 10.1007/s12282-022-01342-4. Epub ahead of print.
    • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.
    • Quesada S, Fabbro M, Solassol J.
    • Cancers (Basel). 2022 Feb 21;14(4):1098. doi: 10.3390/cancers14041098.
    • Saturation variant interpretation using CRISPR prime editing.
    • Erwood S, Bily TMI, Lequyer J, Yan J, Gulati N, Brewer RA, Zhou L, Pelletier L, Ivakine EA, Cohn RD.
    • Nat Biotechnol. 2022 Feb 21. doi: 10.1038/s41587-021-01201-1. Epub ahead of print.
    • Predictors of cardiopulmonary fitness in cancer-affected and -unaffected women with a pathogenic germline variant in the genes BRCA1/2 (LIBRE-1).
    • Berling-Ernst A, Yahiaoui-Doktor M, Kiechle M, Engel C, Lammert J, Grill S, Dukatz R, Rhiem K, Baumann FT, Bischoff SC, Erickson N, Schmidt T, Niederberger U, Siniatchkin M, Halle M.
    • Sci Rep. 2022 Feb 21;12(1):2907. doi: 10.1038/s41598-022-06913-1.
    • PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
    • Bienkowski M, Tomasik B, Braun M, Jassem J.
    • Cancer Treat Rev. 2022 Feb 11;104:102359. doi: 10.1016/j.ctrv.2022.102359. Epub ahead of print.
    • Review